Research Paper Volume 13, Issue 10 pp 14258—14276

LncRNA LOC100129620 promotes osteosarcoma progression through regulating CDK6 expression, tumor angiogenesis, and macrophage polarization

LncRNA LOC100129620 knockdown inhibits the proliferation and invasion of osteosarcoma cells. (A) The expression of LOC100129620 in U2OS cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (B) The expression of LOC100129620 in MG63 and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (C) CCK-8 assay to analyze the viability of U2OS cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (D) CCK-8 assay to analyze the viability of MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (E) Colony formation assay to analyze the proliferation of U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (F) Quantitative analysis of the colony formation assay results of U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (G) Flow cytometry analysis of the cell cycle in U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (H) Flow cytometry analysis of apoptosis of U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (I) Cell scratch assay to detect the migration ability of U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (J) Transwell assay to detect the invasion ability of U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (K) Quantitative analysis of the Transwell assay results of U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. Statistical analysis was conducted using Student’s t-test. Values are means ± SD. *P P

Figure 3. LncRNA LOC100129620 knockdown inhibits the proliferation and invasion of osteosarcoma cells. (A) The expression of LOC100129620 in U2OS cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (B) The expression of LOC100129620 in MG63 and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (C) CCK-8 assay to analyze the viability of U2OS cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (D) CCK-8 assay to analyze the viability of MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (E) Colony formation assay to analyze the proliferation of U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (F) Quantitative analysis of the colony formation assay results of U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (G) Flow cytometry analysis of the cell cycle in U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (H) Flow cytometry analysis of apoptosis of U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (I) Cell scratch assay to detect the migration ability of U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (J) Transwell assay to detect the invasion ability of U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. (K) Quantitative analysis of the Transwell assay results of U2OS and MG63 cells transfected with pLKO.1-Vector, pLKO.1-sh1, or pLKO.1-sh2. Statistical analysis was conducted using Student’s t-test. Values are means ± SD. *P < 0.05 and **P < 0.01.